

PA 1244850

THE UNITED STATES OF AMERICA**TO ALL TO WHOM THESE PRESENTS SHALL COME:****UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office****November 05, 2004**

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.


APPLICATION NUMBER: 60/538,907**FILING DATE: January 23, 2004**

REC'D 14 MAR 2005

WIPO PCT

**PRIORITY
DOCUMENT****SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)**

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**

**P. R. GRANT****Certifying Officer****BEST AVAILABLE COPY**



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

March 10, 2005

Einsender / Sender / Expéditeur :

Janssen Pharmaceutica N.V.
Attn. : Marleen Van Loon - 2238
J&J Patent Law Department
Turnhoutseweg 30
B-2340 Beerse
Belgium

☒ D-80298 München
☎ (+49-89) 2399-0
Tx 523 656 epmu d
Fax (+49-89) 23 99-44 65
☒ P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
☎ (+31-70) 340-2040
Tx 31 651 epo nl
Fax (+31-70) 340-3016
☒ D-10958 Berlin
☎ (+49-30) 25901-0
Fax (+49-30) 25901-840

**Bestätigung über den
Eingang nachgereichter
Unterlagen für Patentan-
meldungen/Patente beim
Europäischen Patentamt**

**Acknowledgement of
receipt for subsequently
filed items relating to
patent applications/patents
at the European Patent
Office**

**Accusé de réception à
l'Office européen des bre-
vets de pièces produites
postérieurement au dépôt
d'une demande de brevet/
à la délivrance d'un brevet
européen**

Datum und Ort des Eingangs sind aus
der Perforation dieser Eingangsbestäti-
gung ersichtlich
(M + Datum = Einreichungsort München;
Datum ohne Zusatz = Einreichungsort
Den Haag; Datum + B = Einreichungsort
Berlin)

Date and place of receipt are shown by
the perforation appearing on this receipt
(M + date = Munich as place of receipt;
date alone = The Hague as place of
receipt; date + B = Berlin as place of
receipt)

La date et le lieu de réception sont indi-
qués par la perforation du présent accusé
de réception
(M + date = pièces reçues à Munich;
date seule = pièces reçues à La Haye;
date + B = pièces reçues à Berlin)

Eingereichte Unterlagen

Items filed

Pièces envoyées

Anmeldungs- (und Direktions-*) Nr./Patent Nr. Application (and Directorate*) No./Patent No. N° de la demande (et de la direction*)/n° du brevet	Ihr Zeichen Your reference Votre référence	ggfs. Art und Datum der Unterlagen** Nature and date of items (optional)** Nature et date des pièces (facultatif)**
1		
2		
3	PCT/EP2005/050271	PRD 2184f-PCT
4		Certified Copy US60/538,907
5		
6		
7		
8		
9		
10		

* falls bereits bekannt

* if already known

* si déjà connu

** Der Eingang der angegebenen Unterlagen
wird bestätigt.
Enthält diese Spalte keine Eintragungen, so
wird lediglich bestätigt, daß eine Sendung
zu dem angegebenen Aktenzeichen einge-
gangen ist.

** The receipt of the items indicated is
confirmed.
If this column does not contain any entries,
it is only confirmed that an item has been
received for the indicated file.

** La réception des pièces indiquées est
confirmée.
Faute de mention dans cette colonne, le
présent accusé de réception se rapporte à
une pièce quelconque envoyée sous la
référence indiquée.



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

March 10, 2005

Einsender / Sender / Expéditeur :

Janssen Pharmaceutica N.V.
Attn. : Marleen Van Loon - 2238
J&J Patent Law Department
Turnhoutseweg 30
B-2340 Beerse
Belgium

☒ D-80298 München
☎ (+49-89) 2399-0
Tx 523 656 epmu d
Fax (+49-89) 23 99-44 65
☒ P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
☎ (+31-70) 340-2040
Tx 31 651 epo nl
Fax (+31-70) 340-3016
☒ D-10958 Berlin
☎ (+49-30) 25901-0
Fax (+49-30) 25901-840

**Bestätigung über den
Eingang nachgereichter
Unterlagen für Patentan-
meldungen/Patente beim
Europäischen Patentamt**

Datum und Ort des Eingangs sind aus
der Perforation dieser Eingangsbestäti-
gung ersichtlich
(M + Datum = Einreichungsort München;
Datum ohne Zusatz = Einreichungsort
Den Haag; Datum + B = Einreichungsort
Berlin)

**Acknowledgement of
receipt for subsequently
filed items relating to
patent applications/patents
at the European Patent
Office**

Date and place of receipt are shown by
the perforation appearing on this receipt
(M + date = Munich as place of receipt;
date alone = The Hague as place of
receipt; date + B = Berlin as place of
receipt)

**Accusé de réception à
l'Office européen des bre-
vets de pièces produites
postérieurement au dépôt
d'une demande de brevet/
à la délivrance d'un brevet
européen**

La date et le lieu de réception sont indi-
qués par la perforation du présent accusé
de réception
(M + date = pièces reçues à Munich;
date seule = pièces reçues à La Haye;
date + B = pièces reçues à Berlin)

Eingereichte Unterlagen

Items filed

Pièces envoyées

Anmeldungs- (und Direktions-*) Nr./Patent Nr. Application (and Directorate*) No./Patent No. N° de la demande (et de la direction*)/n° du brevet	Ihr Zeichen Your reference Votre référence	ggfs. Art und Datum der Unterlagen** Nature and date of items (optional)** Nature et date des pièces (facultatif)**
1		
2		
3	PCT/EP2005/050271	PRD 2184f-PCT
4		Certified Copy US60/538,907
5		
6		
7		
8		
9		
10		

* falls bereits bekannt

* if already known

* si déjà connu

** Der Eingang der angegebenen Unterlagen
wird bestätigt.
Enthält diese Spalte keine Eintragungen, so
wird lediglich bestätigt, daß eine Sendung
zu dem angegebenen Aktenzeichen einge-
gangen ist.

** The receipt of the items indicated is
confirmed.
If this column does not contain any entries,
it is only confirmed that an item has been
received for the indicated file.

** La réception des pièces indiquées est
confirmée.
Faute de mention dans cette colonne, le
présent accusé de réception se rapporte à
une pièce quelconque envoyée sous la
référence indiquée.

PROVISIONAL APPLICATION COVER SHEET

Mail Stop Provisional Patent Application
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53 (c).

31355 U.S. PTO
60/538907

012304

17698 U.S. PTO

DOCKET NUMBER			PRD 2184
INVENTOR(s) / APPLICANT(s)			
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
GUILLEMONT	JÉRÔME EMILE GEORGES		Ande, France
TITLE OF THE INVENTION (280 characters max)			
NOVEL MYCOBACTERIAL INHIBITORS			
CORRESPONDENCE ADDRESS			
Direct all correspondence to: <input checked="" type="checkbox"/> Customer Number 000027777 OR <input type="checkbox"/> Firm of Individual Name:			
ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification	Number of Pages	35	<input type="checkbox"/> Application Data Sheet
<input checked="" type="checkbox"/> Claims	Number of Claims	5	<input type="checkbox"/> CD(s), Number
<input checked="" type="checkbox"/> Drawing(s)	Number of Sheets	0	<input type="checkbox"/> Other (specify)
METHOD OF PAYMENT (check one)			
<input type="checkbox"/> A check or money order is enclosed to cover the Provisional filing fees.		Provisional Filing Fee Amount (\$)	\$ 160.00
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit any overpayment to Deposit Account No. 10-0750-PRD2184			

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE:

TYPED or PRINTED NAME

Jesús Juanós i Timoneda

REGISTRATION NO. 43,332

DATE: January 23, 2004

TELEPHONE (732) 524-1513

PROVISIONAL APPLICATION FILING ONLY

DOCKET NO. PRD 2184

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Applicant: JÉRÔME EMILE GEORGES GUILLEMONT

For : NOVEL MYCOBACTERIAL INHIBITORS

Express Mail Certificate

"Express Mail" mailing number: EF 195557372US


Date of Deposit: January 23, 2004

I hereby certify that this complete Provisional application, including specification pages and claims, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

A Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

Laurie A. Phillips

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)

NOVEL MYCOBACTERIAL INHIBITORS

5 The present invention relates to novel substituted quinoline derivatives useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium* and *M. marinum*.

10 BACKGROUND OF THE INVENTION

Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a serious and potentially fatal infection with a world-wide distribution. Estimates from the World Health Organization indicate that more than 8 million people contract TB each year, and 2 million people die from tuberculosis yearly. In the last decade, TB cases have grown 20% worldwide with the highest burden in the most impoverished communities. If these trends continue, TB incidence will increase by 41% in the next twenty years. Fifty years since the introduction of an effective chemotherapy, TB remains after AIDS, the leading infectious cause of adult mortality in the world. Complicating the TB epidemic is the rising tide of multi-drug-resistant strains, and the deadly symbiosis with HIV. People who are HIV-positive and infected with TB are 30 times more likely to develop active TB than people who are HIV-negative and TB is responsible for the death of one out of every three people with HIV/AIDS worldwide



25 Existing approaches to treatment of tuberculosis all involve the combination of multiple agents. For example, the regimen recommended by the U.S. Public Health Service is a combination of isoniazid, rifampicin and pyrazinamide for two months, followed by isoniazid and rifampicin alone for a further four months. These drugs are continued for a further seven months in patients infected with HIV. For patients infected with multi-drug resistant strains of *M. tuberculosis*, agents such as ethambutol, streptomycin, kanamycin, amikacin, capreomycin, ethionamide, cycloserine, ciprofloxacin and ofloxacin are added to the combination therapies. There exists no single agent that is effective in the clinical treatment of tuberculosis, nor any combination of agents that offers the possibility of therapy of less than six months' duration.

35 There is a high medical need for new drugs that improve current treatment by enabling regimens that facilitate patient and provider compliance. Shorter regimens and those that require less supervision are the best way to achieve this. Most of the benefit from

- treatment comes in the first 2 months, during the intensive, or bactericidal, phase when four drugs are given together; the bacterial burden is greatly reduced, and patients become noninfectious. The 4- to 6-month continuation, or sterilizing, phase is required to eliminate persisting bacilli and to minimize the risk of relapse. A potent sterilizing
5 drug that shortens treatment to 2 months or less would be extremely beneficial. Drugs that facilitate compliance by requiring less intensive supervision also are needed. Obviously, a compound that reduces both the total length of treatment and the frequency of drug administration would provide the greatest benefit.
- 10 Complicating the TB epidemic is the increasing incidence of multi-drug- resistant strains or MDR-TB. Up to four percent of all cases worldwide are considered MDR-TB - those resistant to the most effective drugs of the four-drug standard, isoniazid and rifampin. MDR-TB is lethal when untreated and can not be adequately treated through the standard therapy, so treatment requires up to 2 years of "second-line" drugs. These
15 drugs are often toxic, expensive and marginally effective. In the absence of an effective therapy, infectious MDR-TB patients continue to spread the disease, producing new infections with MDR-TB strains. There is a high medical need for a new drug with a new mechanism of action, which is likely to demonstrate activity against MDR strains.
- 20 The purpose of the present invention is to provide novel compounds, in particular substituted quinoline derivatives, having the property of inhibiting growth of mycobacteria and therefore useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium*, *M. smegmatis* and *M. marinum*.
- 25 Substituted quinolines were already disclosed in US 5,965,572 (The United States of America) for treating antibiotic resistant infections and in WO 00/34265 to inhibit the growth of bacterial microorganisms. None of these publications disclose the substituted quinoline derivatives according to our invention.
- 30


SUMMARY OF THE INVENTION

- The present invention relates to novel substituted quinoline derivatives according to
35 Formula (Ia) and (I-b).




the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, wherein :

- 5 R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;
- P is an integer equal to zero, 1, 2 or 3;
- s is an integer equal zero, 1, 2, 3 or 4;
- 10 R^2 is hydrogen; halo; alkyl; hydroxy; thio; alkyloxy optionally substituted with amino or mono or di(alkyl)amino or a radical of formula



wherein Z is CH_2 , $CH-R^{10}$, O, S, $N-R^{10}$ and t is an integer equal 1 or 2 and the dotted line represents an optional bond; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted with one or two substituents each

independently be selected from alkyloxy or Ar or Het or morpholinyl or

2-oxopyrrolidinyl; Het or a radical of formula  wherein
Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰; t is an integer equal 1 or 2; and the
dotted line represents an optional bond;

5 R³ is alkyl, Ar, Ar-alkyl, Het or Het-alkyl;

q is an integer equal to zero, 1, 2, 3 or 4;

R⁴ and R⁵ each independently are hydrogen, alkyl or benzyl; or

R⁴ and R⁵ together and including the N to which they are attached may form a radical
selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolinyl, 3-
10 pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-
pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl,
piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl,
triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with
alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino,
15 alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl;

R⁶ is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio,
alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or

two vicinal R⁶ radicals may be taken together to form a bivalent radical of formula
=C-C=C-C-;

20 r is an integer equal to 0, 1, 2, 3, 4 or 5; and

R⁷ is hydrogen, alkyl, Ar or Het;

R⁸ is hydrogen or alkyl;

R⁹ is oxo; or

R⁸ and R⁹ together form the radical =N-CH=CH-.

25 R¹⁰ is hydrogen, alkyl, aminocarbonyl, mono-or di(alkyl)aminocarbonyl, Ar,
Het, alkyl substituted with one or two Het, alkyl substituted with one or
two Ar, Het-C(=O)-

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6
carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6
30 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6
carbon atoms attached to a straight or branched saturated hydrocarbon radical
having from 1 to 6 carbon atoms; wherein each carbon atom can be optionally
substituted with halo, hydroxy, alkyloxy or oxo;

Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl,
35 tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each
substituent independently selected from the group of hydroxy, halo, cyano,

nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, alkylcarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl ;

5 **Het** is a monocyclic heterocycle selected from the group of N-phenoxypiperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-
10 dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy ;

halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and
 haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to
15 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbon atoms are substituted with one or more halo-atoms.

 The compounds according to Formula (Ia) and (Ib) are interrelated in that e.g. a
20 compound according to Formula (Ib), with R^9 equal to oxo is the tautomeric equivalent of a compound according to Formula (Ia) with R^2 equal to hydroxy (keto-enol tautomerism).

25 DETAILED DESCRIPTION

 In the framework of this application, alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched
30 saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo. Preferably, alkyl is methyl, ethyl or cyclohexylmethyl.

 In the framework of this application, Ar is a homocycle selected from the group of
35 phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or

dialkylaminocarbonyl. Preferably, Ar is naphthyl or phenyl, each optionally substituted with 1 or 2 halo substituents.


In the framework of this application, Het is a monocyclic heterocycle selected from the group of N-phenoxy piperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl ; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy. Preferably, Het is thienyl.

In the framework of this application, halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbonatoms are substituted with one or more halo-atoms. Preferably, halo is bromo, fluoro or chloro and preferably, haloalkyl is trifluoromethyl.

20

Preferably, the invention relates to compounds of Formula (Ia) and (Ib) wherein :

- R^1 is hydrogen, halo, cyano, Ar, Het, alkyl, and alkyloxy ;
 p is an integer equal to zero, 1, 2, 3 or 4 ;
 R^2 is hydrogen, hydroxy, alkyloxy, alkyloxyalkyloxy, alkylthio or a radical




25 of formula wherein Y is O ;

- R^3 is alkyl, Ar, Ar-alkyl or Het ;
 q is an integer equal to zero, 1, 2, or 3 ;
 R^4 and R^5 each independently are hydrogen, alkyl or benzyl; or
 R^4 and R^5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, imidazolyl, triazolyl, piperidinyl, piperazinyl, pyrazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl and pyrimidinyl ;

30

- R^6 is hydrogen, halo or alkyl ; or
two vicinal R^6 radicals may be taken together to form a bivalent radical of formula

35



- r is an integer equal to 1 ; and

- R^7 is hydrogen ;
 R^8 is hydrogen or alkyl ;
 R^9 is oxo ; or
 R^8 and R^9 together form the radical $=N-CH=CH-$.
- 5 alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms ; or is a a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo or hydroxy ;
- 10 Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each substituent independently selected from the group of halo, haloalkyl, cyano, alkyloxy and morpholinyl ;
- 15 Het is a monocyclic heterocycle selected from the group of N-phenoxypiperidinyl, furanyl, thienyl, pyridinyl, pyrimidinyl ; or a bicyclic heterocycle selected from the group of benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]-dioxolyl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 alkyl substituents ; and
- 20 halo is a substituent selected from the group of fluoro, chloro and bromo.

For compounds according to either Formula (Ia) and (Ib), preferably, R^1 is hydrogen, halo, Ar, alkyl or alkyloxy. More preferably, R^1 is halo. Most preferably, R^1 is bromo.

- 25 Preferably, p is equal to 1.

Preferably, R^2 is hydrogen, alkyloxy or alkylthio. More preferably, R^2 is alkyloxy. Most preferably, R^2 is methyloxy.

- 30 Preferably, R^3 is naphthyl, phenyl or thienyl, each optionally substituted with 1 or 2 substituents, that substituent preferably being a halo or haloalkyl, most preferably being a halo. More preferably, R^3 is naphthyl or phenyl. Most preferably, R^3 is naphthyl.

Preferably, q is equal to zero, 1 or 2. More preferably, q is equal to 1.

35

Preferably, R^4 and R^5 each independently are hydrogen or alkyl, more preferably hydrogen, methyl or ethyl, most preferably methyl.

Preferably R^4 and R^5 together and including the N to which they are attached form a radical selected from the group of imidazolyl, triazolyl, piperidinyl, piperazinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, alkylthio, alkyloxyalkyl or alkylthioalkyl, preferably substituted with alkyl, most
5 preferably substituted with methyl or ethyl.

Preferably, R^6 is hydrogen, alkyl or halo. Most preferably, R^6 is hydrogen. Preferably r is 0, 1 or 2.

10 Preferably, R^7 is hydrogen or methyl.

For compounds according to Formula (Ib) only, preferably, R^8 is alkyl, preferably methyl and R^9 is oxygen.

15 An interesting group of compounds are those compounds according to Formula (Ia), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, in which R^1 is hydrogen, halo, Ar, alkyl or alkyloxy, $p = 1$, R^2 is hydrogen, alkyloxy or alkylthio, R^3 is naphthyl, phenyl or thienyl, each optionally substituted with 1 or 2
20 substituents selected from the group of halo and haloalkyl, $q = 0, 1, 2$ or 3 , R^4 and R^5 each independently are hydrogen or alkyl or R^4 and R^5 together and including the N to which they are attached form a radical selected from the group of imidazolyl, triazolyl, piperidinyl, piperazinyl and thiomorpholinyl, R^6 is hydrogen, alkyl or halo, r is equal to 0 or 1 and R^7 is hydrogen.

25 The pharmaceutically acceptable acid addition salts are defined to comprise the therapeutically active non-toxic acid addition salt forms which the compounds according to either Formula (Ia) and (Ib) are able to form. Said acid addition salts can be obtained by treating the base form of the compounds according to either Formula
30 (Ia) and (Ib) with appropriate acids, for example inorganic acids, for example hydrohalic acid, in particular hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid; organic acids, for example acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid,
35 ethanesulfonic acid, benzenesulfonic acid, *p*-toluenesulfonic acid, cyclamic acid, salicylic acid, *p*-aminosalicylic acid and pamoic acid.

The compounds according to either Formula (Ia) and (Ib) containing acidic protons may also be converted into their therapeutically active non-toxic base addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salts forms comprise, for example, the ammonium salts, the alkaline and earth alkaline metal salts, in particular lithium, sodium, potassium, magnesium and calcium salts, salts with organic bases, e.g. the benzathine, *N*-methyl-D-glucamine, hybramine salts, and salts with amino acids, for example arginine and lysine.

Conversely, said acid or base addition salt forms can be converted into the free forms by treatment with an appropriate base or acid.

The term addition salt as used in the framework of this application also comprises the solvates which the compounds according to either Formula (Ia) and (Ib) as well as the salts thereof, are able to form. Such solvates are, for example, hydrates and alcoholates.

The term "stereochemically isomeric forms" as used herein defines all possible isomeric forms which the compounds of either Formula (Ia) and (Ib) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. More in particular, stereogenic centers may have the *R*- or *S*-configuration; substituents on bivalent cyclic (partially) saturated radicals may have either the *cis*- or *trans*-configuration. Stereochemically isomeric forms of the compounds of either Formula (Ia) and (Ib) are obviously intended to be embraced within the scope of this invention.

Following CAS-nomenclature conventions, when two stereogenic centers of known absolute configuration are present in a molecule, an *R* or *S* descriptor is assigned (based on Cahn-Ingold-Prelog sequence rule) to the lowest-numbered chiral center, the reference center. The configuration of the second stereogenic center is indicated using relative descriptors [*R**,*R**] or [*R**,*S**], where *R** is always specified as the reference center and [*R**,*R**] indicates centers with the same chirality and [*R**,*S**] indicates centers of unlike chirality. For example, if the lowest-numbered chiral center in the molecule has an *S* configuration and the second center is *R*, the stereo descriptor would be specified as *S*-[*R**,*S**]. If "∧" and "⊙" are used : the position of the highest priority substituent on the asymmetric carbon atom in the ring system having the lowest ring number, is arbitrarily always in the "∧" position of the mean plane determined by the ring system. The position of the highest priority substituent on the other asymmetric

carbon atom in the ring system relative to the position of the highest priority substituent on the reference atom is denominated “(”, if it is on the same side of the mean plane determined by the ring system, or “@”, if it is on the other side of the mean plane determined by the ring system.

5

Compounds of either Formula (Ia) and (Ib) and some of the intermediate compounds invariably have at least two stereogenic centers in their structure which may lead to at least 4 stereochemically different structures.

- 10 The tautomeric forms of the compounds of either Formula (Ia) and (Ib) are meant to comprise those compounds of either Formula (Ia) and (Ib) wherein e.g. an enol group is converted into a keto group (keto-enol tautomerism).


- 15 The *N*-oxide forms of the compounds according to either Formula (Ia) and (Ib) are meant to comprise those compounds of either Formula (Ia) and (Ib) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide, particularly those *N*-oxides wherein the nitrogen of the amine radical is oxidized.

- 20 The compounds of either Formula (Ia) and (Ib) as prepared in the processes described below may be synthesized in the form of racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of either Formula (Ia) and (Ib) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or
25 fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of either Formula (Ia) and (Ib) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided
30 that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

- 35 The invention also comprises derivative compounds (usually called “pro-drugs”) of the pharmacologically-active compounds according to the invention, which are degraded *in vivo* to yield the compounds according to the invention. Pro-drugs are usually (but not always) of lower potency at the target receptor than the compounds to which they are degraded. Pro-drugs are particularly useful when the desired compound has chemical

or physical properties that make its administration difficult or inefficient. For example, the desired compound may be only poorly soluble, it may be poorly transported across the mucosal epithelium, or it may have an undesirably short plasma half-life. Further discussion on pro-drugs may be found in Stella, V. J. *et al.*, "Prodrugs", *Drug Delivery Systems*, 1985, pp. 112-176, and *Drugs*, 1985, 29, pp. 455-473.

Pro-drugs forms of the pharmacologically-active compounds according to the invention will generally be compounds according to either Formula (Ia) and (Ib), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, having an acid group which is esterified or amidated. Included in such esterified acid groups are groups of the formula $-\text{COOR}^x$, where R^x is a C_{1-6} alkyl, phenyl, benzyl or one of the following groups :




15

Amidated groups include groups of the formula $-\text{CONR}^y\text{R}^z$, wherein R^y is H, C_{1-6} alkyl, phenyl or benzyl and R^z is $-\text{OH}$, H, C_{1-6} alkyl, phenyl or benzyl.

Compounds according to the invention having an amino group may be derivatised with a ketone or an aldehyde such as formaldehyde to form a Mannich base. This base will hydrolyze with first order kinetics in aqueous solution.

20



The radical may be placed on any available position of the quinoline moiety.

25

The compounds according to the invention have surprisingly been shown to be suitable for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium*, *M. smegmatis* and *M. marinum*. The present invention thus also relates to compounds of

either Formula (Ia) and (Ib) as defined hereinabove, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, for use as a medicine.

5 The invention also relates to a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to the invention. The compounds according to the invention may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for
10 systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical
15 compositions are desirable in unitary dosage form suitable, in particular, for administration orally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or
20 solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise
25 sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also
30 included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.

Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 % by weight, more preferably from 0.1 to 70 % by
35 weight of the active ingredient, and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 weight % of a pharmaceutically acceptable carrier, all percentages being based on the total composition.

The pharmaceutical composition may additionally contain various other ingredients known in the art, for example, a lubricant, stabilising agent, buffering agent, emulsifying agent, viscosity-regulating agent, surfactant, preservative, flavouring or colorant.

5

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated

10

to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof. The daily dosage of the compound according to the invention will, of course, vary with

15 the compound employed, the mode of administration, the treatment desired and the mycobacterial disease indicated. However, in general, satisfactory results will be obtained when the compound according to the invention is administered at a daily dosage not exceeding 1 gram, e.g. in the range from 10 to 50 mg/kg body weight.

20

Further, the present invention also relates to the use of a compound of either Formula (Ia) and (Ib), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, as well as any of the aforementioned pharmaceutical compositions thereof for the manufacture of a medicament for the treatment of mycobacterial

25 diseases.

Accordingly, in another aspect, the invention provides a method of treating a patient suffering from , or at risk of, a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound or pharmaceutical


30 composition according to the invention.

GENERAL PREPARATION


35

The compounds according to the invention can generally be prepared by a succession of steps, each of which is known to the skilled person.

Compounds of formula (Ia) can be prepared by reacting an intermediate of formula (II-a), wherein W_1 represents a suitable leaving group, with $H-R^2$ or with a suitable salt form of R^2 in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol and the like, acetonitrile, or in the presence of a suitable base, such as for example KOH, dipotassium carbonate.



Intermediates of formula (II-a) can be prepared by reacting an intermediate of formula (III-a) with an intermediate of formula (IV) in the presence of a suitable reducing agent, such as for example BuLi, and in the presence of a suitable solvent, such as for example tetrahydrofuran, and a suitable base, such as for example 2,2,6,6-tetramethylpiperidine.




The intermediate compounds of (III-a) are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally

known in the art. For example, intermediates of formula (III-a) wherein s is 1 and R⁷ is hydrogen and W1 is chloro, said intermediates being represented by formula (III-a-1) may be prepared according to the following reaction scheme (1):

Scheme 1

5



(III-a-1)


wherein all variables are defined as in Formula (Ia) and (Ib). Reaction scheme (1) comprises step (a) in which an appropriately substituted aniline is reacted with an appropriate acylchloride such as 3-phenylpropionyl chloride, 3-fluorobenzenepropionyl chloride or p-chlorobenzenepropionyl chloride, in the presence of a suitable base, such as triethylamine and a suitable reaction-inert solvent, such as methylene chloride or ethylene dichloride. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature. In a next step (b) the adduct obtained in step (a) is reacted with phosphoryl chloride (POCl₃) in the presence of N,N-dimethylformamide (Vilsmeier-Haack formylation followed by cyclization). The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature.

It is evident that in the foregoing and in the following reactions, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art, such as extraction, crystallization and chromatography. It is further evident that reaction products that exist in more than one enantiomeric form, may be isolated from their mixture by known techniques, in particular preparative chromatography, such as preparative HPLC. Typically, compounds of Formula (Ia) and (Ib) may be separated into their isomeric forms.

The intermediates of Formula (IV) are compounds that are either commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, intermediate compounds of Formula (IV-a) in which R^3 is Ar substituted with w substituents R^{11} , wherein each R^{11} is independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl and s is an integer equal to zero, 1, 2 or 3, may be prepared according to the following reaction scheme (2):

10

Scheme 2



Reaction scheme (2) comprises step (a) in which an appropriately substituted phenyl is reacted by Friedel-Craft reaction with an appropriate acylchloride such as 3-chloropropionyl chloride or 4-chlorobutyryl chloride, in the presence of a suitable Lewis acid, such as $AlCl_3$, $FeCl_3$, $SnCl_4$, $TiCl_4$ or $ZnCl_2$ and a suitable reaction-inert solvent, such as methylene chloride or ethylene dichloride. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature. In a next step (b) an amino group ($-NR_4(CH_2-C_6H_5)$) is introduced by reacting the intermediate compound obtained in step (a) with a primary or secondary amine.

25

The following examples illustrate the present invention without being limited thereto.

EXPERIMENTAL PART

Of some compounds the absolute stereochemical configuration of the stereogenic carbon atom(s) therein was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration. However, said "A" and "B" isomeric forms can be unambiguously characterized by a person skilled in the art, using art-known methods such as, for example, X-ray diffraction. The isolation method is described in detail below.


10

Hereinafter, "DMF" is defined as *N,N*-dimethylformamide, "DIPE" is defined as diisopropyl ether, "THF" is defined as tetrahydrofuran.

A. Preparation of the intermediate compounds

15 Example A1


Preparation of intermediate compound 1



Benzenepropanoylchloride (0.488 mol) was added dropwise at room temperature to a solution of 4-bromobenzenamine (0.407 mol) in Et_3N (70ml) and CH_2Cl_2 (700ml) and the mixture was stirred at room temperature overnight. The mixture was poured out into water and concentrated NH_4OH , and extracted with CH_2Cl_2 . The organic layer was dried (MgSO_4), filtered, and the solvent was evaporated. The residue was crystallized from diethyl ether. The residue (119.67g) was taken up in CH_2Cl_2 and washed with HCl 1N. The organic layer was dried (MgSO_4), filtered, and the solvent was evaporated. Yielding: 107.67g of intermediate compound 1.

20


Preparation of intermediate compound 9



25 Accordingly, intermediate compound 9 was prepared in the same way as intermediate compound 1 but using 4-methyl-benzenepropanoylchloride.


Example A2

Preparation of intermediate compound 2



The reaction was carried out twice . POCl_3 (1.225 mol) was added dropwise at 10°C to DMF (0.525 mol) . Then intermediate compound 1 (prepared according A1) (0.175 mol) was added at room temperature . The mixture was stirred overnight at 80°C , poured out on ice and extracted with CH_2Cl_2 . The organic layer was dried (MgSO_4), filtered, and the solvent was evaporated . The product was used without further purification. Yielding: (77.62g; Yield=67%) .

Preparation of intermediate compound 10




Accordingly, intermediate compound 10 was prepared in the same way as intermediate compound 2, starting from intermediate compound 9 (prepared according to A1).

10

Example A3


Preparation of intermediate compound 3



A mixture of intermediate compound 2 (prepared according to A2) (0.233 mol) in CH_3ONa (30%) in methanol (222.32 ml) and methanol (776ml) was stirred and refluxed overnight, then poured out on ice and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated . The residue was purified by column chromatography over silica gel (eluent: CH_2Cl_2 /cyclohexane 20/80 and then 100/0; 20-45 μm). The pure fractions were collected and the solvent was evaporated . Yielding: 25g of intermediate compound 3 (Yield=33%; mp. 84°C) as a white powder .

20


Preparation of intermediate compound 11



Accordingly, intermediate compound 11 was prepared in the same way as intermediate compound 3, starting from intermediate compound 10 (prepared according to A2).

Example A4

Preparation of intermediate compound 4




A mixture of intermediate compound 2 (prepared according to A2) (0.045 mol) in NaOEt 21% in ethanol (50ml) and ethanol (150ml) was stirred and refluxed for 12 hours. The mixture was poured out on ice and extracted with CH_2Cl_2 . The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated.

5 Yielding: 15.2g of intermediate compound 4 (98%).

Example A5

Preparation of intermediate compound 5




A mixture of 5-bromo-1H-indole-2,3-dione (0.28 mol) in NaOH 3N (650ml) was stirred and heated at 80°C for 30 min, then cooled to room temperature.

10 Benzenepropanal (0.28 mol) was added and the mixture was stirred and refluxed overnight. The mixture was allowed to cool to room temperature and acidified till $\text{pH}=5$ with HOAc. The precipitate was filtered off, washed with H_2O and dried (vacuum). Yielding: 50g of intermediate compound 5 (52%).

15 Example A6


Preparation of intermediate compound 6




A mixture of intermediate compound 5 (prepared according to A5) (0.035 mol) in diphenylether (100ml) was stirred and heated at 300°C for 8 hours, then allowed to cool to room temperature. This procedure was carried out four times. The four mixtures were combined and then purified by column chromatography over silica gel (eluent: $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 100/0, then 99/1). The pure fractions were collected and the solvent was evaporated. Yielding: 25.6g of intermediate compound 6 (61%).

Example A7

Preparation of intermediate compounds 12 and 13



Intermediate 12




Intermediate 13

A mixture of aluminium chloride (34.3g, 0.257mol) and 3-chloropropionyl chloride (29.7g, 0.234mol) in dichloroethane (150ml) was stirred at 0°C. A solution of naphthalene (30g, 0.234mol) in dichloroethane (50ml) was added. The mixture was stirred at 5°C for 2 hours and poured out into ice water. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (56g) was purified by column chromatography over silica gel (eluent: cyclohexane/ CH₂Cl₂: 60/40; 20-45µm). Two fractions were collected and the solvent was evaporated to afford intermediate compound 12 (31g; Yield=61%) as an oil. The second fraction (14g) was taken up in DIPE to afford intermediate compound 13 (8.2g; Yield=16%; mp.68°C) as a pale yellow solid.

Example A8

Preparation of intermediate compound 14




Intermediate 14

A mixture of the intermediate compound 12 (prepared according to A8) (3g; 0.0137mol), N-benzylmethyl amine (2ml; 0.0150mol) in acetonitrile (100ml) was stirred at 80°C for 2 hours. At room temperature (RT) water was added. The mixture was extracted with CH₂Cl₂. The organic layer was separated and dried (MgSO₄), filtered, and the solvent was evaporated. The residue (6g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/ MeOH: 97/3; 20-45µm) to afford BB1 (4.2g; quantitative yield) as an oil, yielding intermediate compound 14.

Example A9


Preparation of intermediate compound 15



A mixture of 3,5-difluoroacetophenone (commercially available) (25g; 0.16mol), diethylamine hydrochloride (52g; 0.64mol), paraformaldehyde (19g; 0.63mol) in HCl conc (5ml) and ethanol (300ml) was stirred at 80°C for 16 hours. The mixture was evaporated till dryness and the residue was taken up by HCl 3N (50ml). This mixture was extracted with Et₂O (3x30ml). The organic layer was collected and basified with K₂CO₃ (10%aq). The organic layer was dried over MgSO₄ and evaporated. The product, intermediate compound 15 was used without further purification for the next step (23.7g; yield : 69%) as an oil.

10 Example A10

Preparation of intermediate compounds 16 and 17



nBuLi 1.6M (0.127 mol) was added dropwise at -10 °C under N₂ flow to a solution of 2,2,6,6-tetramethylpiperidine (0.12 mol) in THF (200ml) . The mixture was stirred at -10 °C for 20 minutes and then cooled to -70 °C . A solution of intermediate compound 2 (0.1 mol) in THF (100ml) was added . The mixture was stirred at -70°C for 45 minutes . A solution of 3-(dimethylamino)-1-phenyl-1-propanone (0.1 mol) in THF (100ml) was added . The mixture was stirred at -70°C for 1 hour, brought to -50 °C then hydrolysed. Water (100 ml) was added at -50 °C. The mixture was stirred at room temperature for 30 minutes and extracted with EtOAc. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was taken up in EtOAc. The precipitate was filtered off, washed with EtOAc and diethylether and dried in vacuo, yielding 4 g of intermediate compound 17. The mother layer was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1). The desired fractions were collected and the solvent was evaporated. The residue was crystallized from diethyl ether. The precipitate was filtered off and dried, yielding 1 g of intermediate compound 16.

B. Preparation of the final compounds

Example B1

Methanol sodium salt (30%)(2ml) was added at room temperature to a mixture of intermediate (17) (0.002 mol) in methanol (2ml). The mixture was stirred and refluxed overnight, poured out on ice and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was vaporated. The residue (0.62g) was purified by column chromatography over silica gel (eluent:

CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.5; 15-40μm). The pure fractions were collected and the solvent was evaporated, yielding 0.39g of product. This fraction was crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.15g of compound (1); mp. 66°C.

5

Example B2

A mixture of intermediate (17) (0.0019 mol), morpholine (0.0021 mol) and potassium carbonate (0.3g) in acetonitrile (10ml) was stirred and refluxed overnight, poured out on ice and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄),
10 filtered, and the solvent was evaporated. The residue (0.58g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.1 to 94/6/0.5; 15-40μm). Two fractions were collected and the solvent was evaporated, yielding 0.41g of fraction 1 and 0.04g of fraction 2. Fraction 2 was crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.023g of compound (2); ; mp.
15 70°C.

Example B3













A mixture of potassium hydroxide (0.0011 mol) in 1-piperidineethanol (2ml) was stirred at 80°C till potassium hydroxide disappeared. Intermediate (17) (0.0009 mol)
20 was added. The mixture was stirred at 80°C overnight, poured out on ice and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent was evaporated. The residue (2.49g) was crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.308g of compound (3).













Example B4


A mixture of potassium hydroxide (0.0011 mol) in 2-(dimethylamino)ethanol (2ml) was stirred at 80°C for 30 minutes. Intermediate (17) (0.0009 mol) was added. The mixture was stirred at 100°C for a week-end, poured out on ice and extracted with CH₂Cl₂. The organic layer was separated, dried (MgSO₄), filtered, and the solvent
30 was evaporated. The residue (0.66g) was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH 90/10; 10μm). The pure fractions were collected and the solvent was evaporated, yielding 0.38g of product. This fraction was crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.161g of compound (4).















35


The following intermediate and final compounds were prepared according to the methods described above





C. Pharmacological examples

C.1. In-vitro method for testing compounds against *M. tuberculosis*.

Flat-bottom, sterile 96-well plastic microtiter plates were filled with 100 µl of Middlebrook (1x) broth medium. Subsequently, stock solutions (10 x final test concentration) of compounds were added in 25 µl volumes to a series of duplicate wells in column 2 so as to allow evaluation of their effects on bacterial growth. Serial five-fold dilutions were made directly in the microtiter plates from column 2 to 11 using a customised robot system (Zymark Corp., Hopkinton, MA). Pipette tips were changed after every 3 dilutions to minimize pipetting errors with high hydrophobic compounds. Untreated control samples with (column 1) and without (column 12) inoculum were included in each microtiter plate. Approximately 5000 CFU per well of *Mycobacterium tuberculosis* (strain H37RV), in a volume of 100 µl in Middlebrook (1x) broth medium, was added to the rows A to H, except column 12. The same volume of broth medium without inoculum was added to column 12 in row A to H. The cultures were incubated at 37°C for 7 days in a humidified atmosphere (incubator with open air valve and continuous ventilation). One day before the end of incubation, 6 days after inoculation, Resazurin (1:5) was added to all wells in a volume of 20 µl and plates were incubated for another 24 hours at 37°C. On day 7 the bacterial growth was quantitated fluorometrically.

The fluorescence was read in a computer-controlled fluorometer (Spectramax Gemini EM, Molecular Devices) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm. The percentage growth inhibition achieved by the compounds was calculated according to standard methods, and MIC data (representing IC90's expressed in microgram/ml) were calculated.

C.2. In-vitro method for testing compounds for anti-bacterial activity against strain *M. Smegmatis* ATCC607.

Flat-bottom, sterile 96-well plastic microtiter plates were filled with 180 µl of sterile deionized water, supplemented with 0.25 % BSA. Subsequently, stock solutions (7.8 x final test concentration) of compounds were added in 45 µl volumes to a series of duplicate wells in column 2 so as to allow evaluation of their effects on bacterial growth. Serial five-fold dilutions (45 µl in 180 µl) were made directly in the microtiter plates from column 2 to 11 using a customised robot system (Zymark Corp., Hopkinton, MA). Pipette tips were changed after every 3 dilutions to minimize pipetting errors with high hydrophobic compounds. Untreated control samples with (column 1) and without (column 12) inoculum were included in each microtiter plate. Approximately 250 CFU per well of bacteria inoculum, in a volume of 100 µl in 2.8x

Mueller-Hinton broth medium, was added to the rows A to H, except column 12. The same volume of broth medium without inoculum was added to column 12 in row A to H. The cultures were incubated at 37°C for 48 hours in a humidified 5% CO₂ atmosphere (incubator with open air valve and continuous ventilation). At the end of incubation, two days after inoculation, the bacterial growth was quantitated fluorometrically. Therefore Alamar Blue (10x) was added to all wells in a volume of 20 µl and plates were incubated for another 2 hours at 50°C.



The fluorescence was read in a computer-controlled fluorometer (Cytofluor, Biosearch) at an excitation wavelength of 530 nm and an emission wavelength of 590 nm (gain 30). The % growth inhibition achieved by the compounds was calculated according to standard methods. The pIC₅₀ was defined as the 50 % inhibitory concentration for bacterial growth. The results are shown in Table 1.

Table 1 : Results of an in vitro-screening of the compounds according to the invention for *M. smegmatis* (pIC₅₀).

Co.No.	pIC ₅₀
1	5.9
2	5.8

CLAIMS

1. A compound according to the general Formula (Ia) or the general Formula (Ib)




the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the *N*-oxide forms thereof, wherein :

- 10 R^1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl ;
- p is an integer equal to zero, 1, 2 or 3;
- s is an integer equal zero, 1, 2, 3 or 4;
- 15 R^2 is hydrogen; halo; alkyl; hydroxy; thio; alkyloxy optionally substituted with amino or mono or di(alkyl)amino or a radical of formula



wherein Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰ and t is an integer equal 1 or 2 and the dotted line represents an optional bond; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted with one or two substituents each independently be selected from alkyloxy or Ar or Het or morpholinyl or



2-oxopyrrolidinyl; Het or a radical of formula wherein Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰; t is an integer equal 1 or 2; and the dotted line represents an optional bond;

R³ is alkyl, Ar, Ar-alkyl, Het or Het-alkyl;

q is an integer equal to zero, 1, 2, 3 or 4;

R⁴ and R⁵ each independently are hydrogen, alkyl or benzyl; or

R⁴ and R⁵ together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl;

R⁶ is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or

two vicinal R⁶ radicals may be taken together to form a bivalent radical of formula =C-C=C-C-;

r is an integer equal to 0, 1, 2, 3, 4 or 5; and

R⁷ is hydrogen, alkyl, Ar or Het;


R⁸ is hydrogen or alkyl;

R⁹ is oxo; or

R⁸ and R⁹ together form the radical =N-CH=CH-.


R¹⁰ is hydrogen, alkyl, aminocarbonyl, mono- or di(alkyl)aminocarbonyl, Ar, Het, alkyl substituted with one or two Het, alkyl substituted with one or two Ar, Het-C(=O)-

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical



wherein Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰ and t is an integer equal 1 or 2 and the dotted line represents an optional bond; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted with one or two substituents each

5



2-oxopyrrolidinyl; Het or a radical of formula wherein Z is CH₂, CH-R¹⁰, O, S, N-R¹⁰; t is an integer equal 1 or 2; and the dotted line represents an optional bond;

R³ is alkyl, Ar, Ar-alkyl, Het or Het-alkyl;

10 q is an integer equal to zero, 1, 2, 3 or 4;


R⁴ and R⁵ each independently are hydrogen, alkyl or benzyl; or

R⁴ and R⁵ together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2H-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolyl, 2-pyrazolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, imidazolidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, optionally substituted with alkyl, halo, haloalkyl, hydroxy, alkyloxy, amino, mono- or dialkylamino, alkylthio, alkyloxyalkyl, alkylthioalkyl and pyrimidinyl;

15

20 R⁶ is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or

two vicinal R⁶ radicals may be taken together to form a bivalent radical of formula



r is an integer equal to 0, 1, 2, 3, 4 or 5; and

25 R⁷ is hydrogen, alkyl, Ar or Het;

R⁸ is hydrogen or alkyl;

R⁹ is oxo; or

R⁸ and R⁹ together form the radical =N-CH=CH-.

R¹⁰ is hydrogen, alkyl, aminocarbonyl, mono- or di(alkyl)aminocarbonyl, Ar, Het, alkyl substituted with one or two Het, alkyl substituted with one or two Ar, Het-C(=O)-

30

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms; or is a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms attached to a straight or branched saturated hydrocarbon radical

35

having from 1 to 6 carbon atoms ; wherein each carbon atom can be optionally substituted with halo, hydroxy, alkyloxy or oxo ;

Ar is a homocycle selected from the group of phenyl, naphthyl, acenaphthyl, tetrahydronaphthyl, each optionally substituted with 1, 2 or 3 substituents, each
5 substituent independently selected from the group of hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, haloalkyloxy, carboxyl, alkyloxycarbonyl, alkylcarbonyl, aminocarbonyl, morpholinyl and mono- or dialkylaminocarbonyl ;

Het is a monocyclic heterocycle selected from the group of N-phenoxypiperidinyl, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a
10 bicyclic heterocycle selected from the group of quinolinyl, quinoxalinyl, indolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo[1,4]dioxinyl or benzo[1,3]dioxolyl ; each monocyclic and
15 bicyclic heterocycle may optionally be substituted on a carbon atom with 1, 2 or 3 substituents selected from the group of halo, hydroxy, alkyl or alkyloxy ;

halo is a substituent selected from the group of fluoro, chloro, bromo and iodo and
haloalkyl is a straight or branched saturated hydrocarbon radical having from 1 to
20 6 carbon atoms or a cyclic saturated hydrocarbon radical having from 3 to 6 carbon atoms, wherein one or more carbon atoms are substituted with one or more halo-atoms.

2. A compound according to claim 1 for use as a medicine.

25

3. A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in claim 1.



4. Use of a compound according to claim 1 or a composition according to claim 3 for the
30 manufacture of a medicament for the treatment of mycobacterial diseases.

5 Method of treating a patient suffering from, or at risk of, a mycobacterial disease, which comprises administering to the patient a therapeutically effective amount of a compound according to claim 1 or pharmaceutical composition according to claim 3.

35

ABSTRACT NOVEL MYCOBACTERIAL INHIBITORS

- 5 The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib)



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, ~~the tautomeric~~ forms thereof and the *N*-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as *Mycobacterium tuberculosis*, *M. bovis*, *M. avium*, *M. smegmatis* and *M. marinum*. In particular, compounds are claimed in which, independently from each other, R¹ is bromo, p=1, R² is alkyloxy, R³ is optionally substituted naphthyl or phenyl, q=1, R⁴ and R⁵ each independently are hydrogen, methyl or ethyl, R⁶ is hydrogen, r is equal to 0 or 1 and R⁷ is hydrogen. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the

manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.